摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2,3,3-tetramethyl-butyric acid amide | 98486-62-5

中文名称
——
中文别名
——
英文名称
2,2,3,3-tetramethyl-butyric acid amide
英文别名
2,2,3,3-Tetramethyl-buttersaeure-amid;2,2,3,3-tetramethyl-butyramide;t-Butyl-dimethylacetamide;2,2,3,3-tetramethylbutanamide
2,2,3,3-tetramethyl-butyric acid amide化学式
CAS
98486-62-5
化学式
C8H17NO
mdl
MFCD19203829
分子量
143.229
InChiKey
SSZQEHNUYPQGII-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.875
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    1

反应信息

  • 作为反应物:
    描述:
    2,2,3,3-tetramethyl-butyric acid amide 在 phosphorus pentoxide 作用下, 生成 2,2,3,3-tetramethyl-butyronitrile
    参考文献:
    名称:
    Whitmore; Marker; Plambeck, Journal of the American Chemical Society, 1941, vol. 63, p. 1628
    摘要:
    DOI:
  • 作为产物:
    描述:
    2,2,3,3-tetramethylbutyric acid chloride 作用下, 以 四氢呋喃 为溶剂, 以57.8%的产率得到2,2,3,3-tetramethyl-butyric acid amide
    参考文献:
    名称:
    Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
    摘要:
    一种异戊酰胺类似物,相比异戊酰胺,至少具有增强的效力、延长的半衰期和增强的稳定性中的一种。该异戊酰胺类似物是环状类似物或非环状类似物。该异戊酰胺类似物被制成药物组合物。还揭示了一种治疗中枢神经系统疾病或疾病的方法。该方法包括向患有中枢神经系统疾病或疾病的患者施用异戊酰胺类似物。
    公开号:
    US20060025477A1
点击查看最新优质反应信息

文献信息

  • Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
    申请人:Vertex Pharmaceuticals Incorporated
    公开号:US20150231142A1
    公开(公告)日:2015-08-20
    The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.
    本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物(A式、B式、C式或D式)的药物组合物。该发明还涉及这些药物配方,以及使用这些组合物治疗CFTR介导的疾病,特别是囊性纤维化的方法。
  • FUSED PYRIMIDINE COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR, AND COMPOSITION AND APPLICATION THEREOF
    申请人:SHANGHAI YINGLI PHARMACEUTICAL CO., LTD
    公开号:US20160214994A1
    公开(公告)日:2016-07-28
    Disclosed are a fused pyrimidine compound, an intermediate, a preparation method therefor, and a composition and an application thereof. The present invention provides a fused pyrimidine compound shown in formula I, pharmaceutically acceptable salt, hydrate, solvate, and an optical isomer or prodrug of the compound. The present invention further provides applications of the fused pyrimidine compound shown in formula I, the pharmaceutically acceptable salt, the hydrate, solvate, and the optical isomer or the prodrug of the compound in the preparing drugs for curing and/or preventing a kinase-related disease. The fused pyrimidine compound I of the present invention is an efficient PI3 kinase depressor, and can be used to prepare drugs for preventing and/or curing cell-proliferation diseases such as cancer, infection, inflammation, and an autoimmune disease.
    揭示了一种融合嘧啶化合物,其中间体,制备方法以及其组成和应用。本发明提供了一种如式I所示的融合嘧啶化合物,该化合物的药用可接受盐,水合物,溶剂合物,以及光学异构体或前药。本发明还提供了应用式I所示的融合嘧啶化合物,药用可接受盐,水合物,溶剂合物,以及该化合物的光学异构体或前药在制备用于治疗和/或预防激酶相关疾病的药物中。本发明的融合嘧啶化合物I是一种高效的PI3激酶抑制剂,可用于制备用于预防和/或治疗细胞增殖性疾病,如癌症,感染,炎症和自身免疫疾病的药物。
  • FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES
    申请人:GRUNENTHAL GMBH
    公开号:US20140066426A1
    公开(公告)日:2014-03-06
    The invention relates to pyrrole carboxamides bearing a fluoromethyl-moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    这项发明涉及带有氟甲基基团的吡咯酮羧酰胺作为电压门控钙通道阻滞剂,以及含有这些化合物的药物组合物,还涉及这些化合物用于治疗和/或预防疼痛以及其他疾病和/或紊乱。
  • Analogs of isovaleramide, a pharmaceutical composition including the same, and a method of treating central nervous system conditions or diseases
    申请人:Artman D. Linda
    公开号:US20060025477A1
    公开(公告)日:2006-02-02
    An isovaleramide analog having at least one of an increased potency, an increased half-life, and an increased stability compared to isovaleramide. The isovaleramide analog is a cyclic analog or a noncyclic analog. The isovaleramide analog is formulated into a pharmaceutical composition. A method of treating a central nervous system condition or disease is also disclosed. The method comprises administering an isovaleramide analog to a patient suffering from the central nervous system condition or disease.
    一种异戊酰胺类似物,相比异戊酰胺,至少具有增强的效力、延长的半衰期和增强的稳定性中的一种。该异戊酰胺类似物是环状类似物或非环状类似物。该异戊酰胺类似物被制成药物组合物。还揭示了一种治疗中枢神经系统疾病或疾病的方法。该方法包括向患有中枢神经系统疾病或疾病的患者施用异戊酰胺类似物。
  • PYRROLO-PYRIMIDINE DERIVATIVE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME COMPOUND AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
    申请人:DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION
    公开号:US20200239474A1
    公开(公告)日:2020-07-30
    The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.
    本发明涉及一种新型吡咯-嘧啶衍生物化合物,其制备方法和制备以该化合物为有效成分的药物组合物,用于预防或治疗蛋白激酶相关疾病。根据本发明,化学式1所表示的化合物、其光学异构体或其药学上可接受的盐,以及包含其作为有效成分的药物组合物,具有对LRRK2激酶和对NIH-3T3细胞系(一种LRRK2表达细胞系)以及NCC01和448T细胞系(均来源于脑肿瘤患者)的磷酸化具有显著的抑制活性。该化合物已经被证实对除LRRK2外的各种蛋白激酶具有抑制活性,因此可以在蛋白激酶相关疾病的治疗或预防中发挥有效作用。
查看更多